Sigyn Therapeutics
Pre-clinicalSigyn CardioDialysis™ aims to reduce the circulating presence of inflammatory molecules and cholesterol-transporting lipoproteins that increase Major Adverse Cardiovascular Events (MACE).
Founded
2019
Focus
Infectious Disease
About
Sigyn CardioDialysis™ aims to reduce the circulating presence of inflammatory molecules and cholesterol-transporting lipoproteins that increase Major Adverse Cardiovascular Events (MACE).
Funding History
1SeedUndisclosedUndisclosedJun 15, 2020
Company Info
TypePrivate
Founded2019
LocationSan Diego, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile